Format

Send to

Choose Destination
Clin Liver Dis. 2019 Aug;23(3):521-534. doi: 10.1016/j.cld.2019.04.012. Epub 2019 Jun 5.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

Author information

1
Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia; University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia. Electronic address: j.sasadeusz@mh.org.au.
2
Olivia Newton John Cancer Research Institute, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia.
3
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia.
4
National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore.
5
University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia.
6
University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia.
7
St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.
8
University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA.
9
Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia.
10
Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia; Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia.
11
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia; Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia.
12
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.
13
The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia; Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia.
14
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia.
15
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA.

Abstract

Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.

KEYWORDS:

Anti-CD20; Direct-acting antivirals; Hepatitis B; Inflammatory bowel diseases; Reactivation; Rheumatoid arthritis

PMID:
31266625
DOI:
10.1016/j.cld.2019.04.012

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center